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ABSTRACT 
Advances in medical capability should be accompanied by discussion of their ethical 
implications. In the military medical context there is a growing interest in developing 
prophylactic interventions that will mitigate the effects of trauma and improve survival. 
The ethics of this novel capability are currently unexplored. This paper describes the 
concept of trauma prophylaxis (Left Of Bang Interventions in Trauma) and outlines some 
of the ethical issues that need to be considered, including within concept development, 
research, and implementation. Trauma prophylaxis can be divided into interventions that 
do not (type 1) and those that do (type 2) have medical enhancement as an unintended 
side effect of their prophylactic action. We conclude that type 1 interventions have much 
in common with established military medical prophylaxis, and the potentially enhancing 
qualities of type 2 interventions raise different issues. We welcome further debate on 
both interventions. 
 
INTRODUCTION 
Combat trauma can have devastating effects on both survival and long-term physical and 
psychological function. Modern trauma care for the war-wounded has advanced 
markedly during the recent conflicts in Iraq and Afghanistan. Further improvements may 
require a conceptual shift towards medical intervention before injury occurs. Eisenstein et 
al outlined such a strategy, coining the term “Left Of Bang Interventions in Trauma” 
(LOB-IT), as a reference to traditional military medical timeline schemata where events 
are depicted as occurring from left to right as time progresses. A LOB-IT is “any medical, 
pharmacological, or surgical intervention that is delivered before trauma in order to 
reduce morbidity and mortality following injury”[1]. Recently, there has been an increase 
in basic science and observational clinical studies exploring the potential for LOB-IT to 
improve mortality and outcomes after injury.[2-5] No LOB-IT has yet been tested in 
humans, but may be justified if further improvements in trauma survival and outcomes 
are to be realised. Trials of LOB-ITs may raise ethical concerns given the novelty of the 
ideas involved and the military context. In this paper we will summarise and explore 
some of these concerns in relation to the ethics of prophylaxis use, clinical research, 
military medicine, and human enhancement, in order to promote further discussion 
amongst civilian and military ethicists alike.   
 
There are two ethically distinct categories of LOB-ITs: Type 1 are those that are purely 
prophylactic; and Type 2 are those that may have both prophylactic and enhancing 
properties (for example a beneficial augmentation of strength or physical reserve in 
addition to their prophylactic effects).[6] A hypothetical example of a Type 1 LOB-IT may 
be tranexamic acid (TXA), and, an equally hypothetical example of a Type 2 LOB-IT may 
be erythropoietin (EPO) (see Table 1). For the purpose of this paper, we will assume that 
any performance-enhancing side-effects of LOB-ITs are unintended consequences of a 
primary intention to reduce morbidity and mortality after trauma. Nonetheless, the ethical 
implications of these enhancement properties cannot be ignored.  
  
 Table 1. Examples of potential Type 1 and Type 2 left of bang interventions in 
trauma 
 
Type of intervention Rationale 
Type 1 
 
Eg. Tranexamic acid 
(TXA) 
Reduces mortality after trauma. The earlier TXA was given 
after injury, the greater its effect on reducing mortality.[7]  
 
Routine administration of TXA preoperatively reduces blood 
loss.[8] 
Type 2 
 
Eg. Erythropoietin 
(EPO) 
May confer survival advantage if given before trauma due to its 
enhancing effects on red blood cell number and volume (well 
known through its use as a performance-enhancing drug in 
competitive sports.[4, 9]) 
 
 
TYPE 1: PURELY PROPHYLACTIC LEFT-OF-BANG INTERVENTIONS 
 
Current military use of prophylaxis centres on infectious diseases. Vaccinations and anti-
malarial drugs are routinely offered to military personnel when the level of risk from the 
infectious disease and the benefits of avoiding or ameliorating infection outweigh the 
risks from the prophylaxis. Both trauma and infectious diseases are threats to life and 
health that can be predicted temporally and geographically. In addition, both cause a 
significant burden to military personnel and capability, and the deleterious effects of both 
may be mitigated through the use of prophylaxis. However, whilst there is significant 
evidence of the efficacy of infectious disease prophylaxis, there are no human data for 
trauma. The acceptability of trials to test the potential benefits of such an intervention 
may depend upon an understanding and acceptance of the ethical equivalence between 
Type 1 (non-enhancing) LOB-IT and current prophylaxis. The advent of pre-exposure 
prophylaxis (PrEP) for HIV infection has resulted in a renewed interest in the principles of 
prophylaxis more generally (Table 2). 
 
Table 2 – Ethical Principles of Prophylaxis Relevant to LOB-IT (from Sugarman and 
Mayer 2013[10] and WHO 2014[11]) 
 
Wellbeing / 
Utility 
The benefits of the prophylaxis must outweigh the harms 
Safety Apart from direct side effects, consideration must be given to the 
potential risks of the prophylaxis, e.g. consequences of imperfect 
adherence 
Parameters of 
Use 
If data on safe and effective use is limited, prophylaxis must only be 
used within the limits of these data, i.e. generalisability to different 
populations or uses must not be assumed 
Risk 
Behaviours 
Steps must be taken to educate recipients about avoidance of risk 
compensation and to monitor changes in risk-related behaviour 
Stigma Consideration must be given to how others may perceive those 
receiving prophylaxis, e.g. difficulties obtaining insurance 
Diversion In resource poor settings, there is a possibility that drugs that can be 
used to treat extant conditions are diverted to prevent the same or other 
conditions 
Equity / 
Justice 
There should be a fair distribution of risks and benefits amongst the 
relevant population 
Access Prophylaxis must be acceptable to the population at risk. This includes 
both the formulation of the treatment and the system of provision 
Competing 
Priorities 
Consideration must be given to how to distribute risks and benefits 
fairly. What “fairness” means may change over time and depends on 
available resources, risk environment, and societal norms 
 
 
Utility 
 
Like any prophylaxis, there needs to be a careful analysis of the balance of risks and 
benefits of either taking or not taking LOB-ITs. In the context of trauma, this analysis will 
have to take account of the likelihood, severity and timing of injury, the efficacy of the 
prophylaxis, any adverse effects, and any possible impact of prophylaxis on risk-taking 
behaviour. LOB-IT is a new concept and currently has no direct data to inform our 
understanding of the magnitude of risks and benefits of the equation. Whilst significant 
historical and pre-clinical data are available, the principle of ‘Parameters of Use’ (Table 2) 
demands that clinical trials will be required to establish safety and efficacy. Such trials 
would need to conform to the accepted ethical frameworks for clinical research. These 
are summarised in Table 3. 
 
 
Table 3: Ethical Principles of Clinical Research (Modified from Emanuel et al. 
2000[12] and NIH Clinical Research Guidance 2016[13]) 
 
Social and clinical 
value 
The answer to research question must be of value to society 
 
Scientific validity 
 
The research question must be answerable and the methods used 
to do so must be valid and feasible 
Fair subject 
selection 
 
The scientific goals of the study (rather than unrelated factors) 
should dictate the choice of group from which individuals are 
chosen 
Favourable risk-
benefit ratio 
The risks to the participants must be minimised and must be 
proportional to the potential benefit to society 
Independent 
review 
An independent review panel should review the proposed research 
to prevent bias, protect participants, assess risks and benefits, and 
ensure that the research is ethical 
Informed Consent 
 
Subjects must: 1) Be informed of the risks, benefits, purpose, 
alternatives, and methods of the research, 2) Understand how this 
research relates to their own interests, 3) Make their decision 
about whether or not to participate voluntarily 
Respect for 
potential and 
enrolled subjects 
 
Researchers should have respect for participants’ privacy and their 
right to change their mind about on going involvement in the 
research. Participants’ welfare should be monitored during and 
after the study. Researchers should share the study findings with 
the participants 
 
Accountability and responsibility 
Even if Type 1 LOB-ITs are to be considered ethically equivalent to other forms of 
prophylaxis, they still raise ethical issues in relation to acceptability and corporate 
responsibility. Prophylaxis in the military has not been without controversy, with widely 
publicised debate surrounding biological and chemical weapon prophylaxis in the first 
Gulf War, as well as more recent criticism of the choice of antimalarial prophylaxis agents. 
[14-16] Controversies such as these have the potential to erode trust in military medical 
prophylaxis despite little evidence of harm attributable to these prophylaxes. Thus, if 
LOB-ITs are going to be acceptable for use, it will not be sufficient to ensure safe, open, 
and ethical trials; it will also be necessary to consult potential user groups about the very 
idea of LOB-IT in advance of such trials. 
 
One may ask whether LOB-IT is solely a military medical issue. The answer is that the 
population LOB-IT is most likely to benefit is that of the military because this population 
has a high and a potentially predictable risk profile. Even within the military, there are 
only particular sub-populations and activities that would confer a sufficiently high level of 
risk to justify the administration of LOB-IT. Thus, given that the population at risk is a 
military one, special ethical considerations of military medicine also apply. 
 
Special military considerations 
One of the key ethical challenges in military medicine is the balance between respect for 
individual autonomy and wellbeing, and the achievement of military objectives. Medical 
interventions have a special ethical status both in civilian and military settings. To 
illustrate this special status one can compare the ethics of non-medical versus medical 
protection. In the UK armed forces, combatants are ordered to wear personal protective 
equipment (PPE) such as body armour and hearing protection despite theoretical risks of 
heat injury or reduced situational awareness respectively. Ordering individual combatants 
to wear PPE is justified because the benefits (protection from ballistic wounding and 
noise-induced hearing loss respectively) outweigh the risks. Moreover, an injured 
individual may affect operational effectiveness of the entire formation. Medical 
prophylaxis, however, is not regarded in the same way. If combatants decline to take 
prophylaxis, there may be adverse consequences of so doing such as exclusion from 
military operations in endemic areas, and they may face sanctions (from the non-medical 
chain of command) for deliberately rendering themselves unfit for duty. One difference in 
approach to compulsion is that medical prophylaxis is prescribed by doctors, who have to 
adhere to their professional code of conduct as well as to military codes (previously 
described as “dual-loyalty[17]). The former prohibits coercive treatment in most 
circumstances partly out of respect for individual patient autonomy and partly to protect 
individual doctor-patient relationships. Public health may be an exception to this general 
rule. Here the interests of the population may override those of the individual. The state 
can legislate to provide prophylaxis to entire populations e.g. fluoridation in water, folic 
acid in bread, though unlike vaccinations – which are compulsory in some jurisdictions – 
these measures are not prescribed or administered by doctors/healthcare professionals. 
Furthermore, even when individuals cannot be forced to receive treatment in their own 
interests, they can face compulsory quarantine in the interests of the population. 
 
The military forms a particular community within the general population and operates to 
different norms. In most NATO-allied nations, the decision to join the armed forces is a 
prima facie voluntary one. Its voluntariness has, however, been questioned. The socio-
economic and race structure of, particularly, the US military, a paucity of other job 
opportunities in generally disadvantaged groups, and opportunities such as 
free/subsidised education and free/subsidised medical care provided to family members 
of serving personnel may result in some economic coercion to join the military.[18] 
Enlistment is, however, undertaken in the knowledge that it entails a significant reduction 
in self-determination (e.g. the requirement to wear a uniform, loss of privacy, obedience 
to the chain of command including to being placed in harm’s way). In addition, other 
values gain heightened significance. In the British Army, for example, these are 
institutionalised as “The Army’s Core Values”: courage, discipline, respect for others, 
integrity, loyalty, and selfless commitment.[19] Adherence to these values, when 
combined with some loss of self-determination, may impact on the way that decisions are 
made in terms of consent and cooperation with large scale prophylaxis programmes, 
including potential LOB-ITs. The emphasis on selflessness and loyalty may mean that 
military personnel are more likely to feel a moral obligation to agree to being exposed to 
LOB-ITs, even if there were no obvious gains for the individual. Furthermore, practicing 
courage and integrity may lead military personnel to consider adherence to prophylaxis 
guidelines one of their duties, even if those interventions have uncertain efficacy. These 
factors, the voluntariness, or otherwise, of the decision to join the military, a reduction in 
self-determination of soldiers and adherence to institutionalised values may vary from 
military to military and, indeed between individuals in the same military and should be 
taken into account when developing novel medical interventions. 
 
The interplay between wider social norms and rights, and those governing military 
service is therefore a complex one. Drugs prescribed and ingested during ‘on-duty’ 
periods will continue to have effects during ‘off-duty’ periods (and may have life-long 
consequences), as indeed may the regimes of physical exercise. Military medical 
professionals are both subject to the military chain of command and are required by their 
professional regulatory bodies to adhere to professional codes of conduct whenever and 
wherever they are practicing. The tension that this creates for practitioners is well known, 
with some arguing that that doctors’ professional ethics pertain even when they practice 
in the military environment, whilst others assert that the military context calls for a 
fundamental re-understanding of military medical ethics.[17, 20] 
 Military organisations make considerable investments in their medical services; 
especially those that address immediate combat injuries. In addition, heroic efforts may 
be made to retrieve and evacuate injured personnel putting further lives at risk. However, 
despite these significant financial and manpower commitments, medical resources may 
be limited for reasons of operational necessity. An injured combatant may use resources 
that will not then be available for the next casualty and these implications merit 
consideration in the military setting, as we will now discuss. Civilian patients are not 
normally expected to consider the interests that other patients might have in the 
resources necessary to treat them. This does not, however, mean that patients do not 
have responsibilities to protect themselves against adverse health events and to limit 
demands on health services.[21] These responsibilities may be heightened when the 
costs and benefits of resources are shared not impersonally between fellow citizens, but 
between close friends or family members. Consider, for instance, live kidney donation by 
parents to their children where parents willingly undertake burdens and risks to their 
health to benefit that of their child. Combatants share a special relationship that may be 
closer to that of family members than that of a group of strangers. Moreover, in combat 
scenarios the uninjured survival of each member of the group adds to the chances of 
survival of the whole group. Each member of the group has a vested interest not only in 
being uninjured themselves, but also in their fellow members being uninjured. Measures 
that lessen the chances or impact of injury are, therefore, arguably in the interests of all. 
Respect for autonomy may justify affording individuals the freedom to take risks that 
affect only themselves. It is less clear that individuals should be similarly free to do as 
they wish when it comes to taking risks that have negative consequences for others. 
Consideration going forward, therefore needs to be given to whether individual 
combatants at particularly high risk could be required to take prophylaxis in these 
circumstances. The values and norms of the military community suggest that individuals 
should (or are likely to) be willing to take prophylaxis in the interests their colleagues but 
this is in part an empirical question that also requires further investigation. 
 
Are type 1 left-of-bang interventions different to other forms of prophylaxis? 
Two common threats that current military prophylaxis seeks to mitigate are infectious 
disease and chemical agent injury. Infectious disease differs because vaccines and other 
prophylaxis (such as for malaria) may completely prevent the disease occurring in the 
first place. In contrast, chemical weapon prophylaxis and LOB-ITs can only reduce 
mortality and morbidity, not eliminate them altogether. Another difference is that 
infectious disease prophylaxis can confer herd immunity (where subtotal administration in 
a population confers protection to those who have not received the prophylaxis because 
the reservoirs and / or vectors of that disease are reduced) whereas other prophylaxis 
cannot do so. As discussed above, LOB-IT-unprotected individuals within a largely LOB-
IT-protected group may still gain a survival advantage because the group may have an 
overall greater chance of survival. From a pragmatic standpoint, LOB-ITs have more in 
common with prophylaxis against chemical weapons than prophylaxis against infectious 
disease. Since chemical weapon prophylaxis is current accepted practice in the 
appropriate threat environment, Type 1 LOB-ITs could be similarly justified. 
 
Might trauma prophylaxis encourage more risky behaviour? 
One question relating to all prophylaxis is whether or not it leads to “risk 
compensation”.[22] The basis of risk compensation is that a perceived protection from 
risk may lead to higher-risk behaviour, and thus an equal or greater overall risk to the 
individual (or group). In the military context this could result in individuals being more 
willing to take risks during combat, which could be seen as beneficial to the combat effort 
if this increases the likelihood of achieving the mission objective. Equally, a commander 
might be willing to accept greater risk to his/her troops if he/she thought that they were 
protected by prophylaxis. This phenomenon has been discussed in non-military contexts, 
particularly when relating to cycle helmet wearing and HIV prophylaxis, but high quality 
evidence of a consistent effect is lacking and the relevance to the military context is 
unknown.[23, 24] In any future LOB-IT discussion or trials, attention must be given to the 
second order effects, such as impact on the decision-making of the chain of command or 
individuals, as well as the purely medical effects. 
 
 
TYPE 2: PROPHYLAXIS WITH POTENTIAL ENHANCEMENT 
 
In addition to a survival or trauma mitigation advantage, some LOB-ITs might confer a 
performance advantage that can be defined as an enhancement (see Table 1). Juengst 
described an enhancement as a medical or biological intervention designed “to improve 
performance, appearance or capability besides what is necessary to achieve, sustain or 
restore health”.[25] Some interventions that are banned in competitive sports are 
considered to increase the physiological reserve of those taking them, resulting in 
improved strength and stamina. The potential military advantages of enhancement 
interventions may be, for example, that those taking them are able to carry heavier loads 
(ammunition, weapons, water, rations), travel further, and fight for longer. 
 
The arguments against the use of performance enhancing drugs in competitive sport 
range from issues of safety to more general concerns about fairness during competition 
and the diminution of what it means to be human. Some of these arguments may be 
used in the case of enhancement in the military, but the analogy between sport and 
combat is an imperfect one. There are no “doping” rules in warfare since there is no 
requirement for battles to be fought on a level playing field beyond that which is 
stipulated in the international law of armed conflict. Indeed, performance enhancing drug-
use in the military has been widely reported. The use of central nervous system 
stimulants in pilots to overcome fatigue, including by US pilots during the Vietnam 
war[26], the Gulf war[27], and the recent Afghanistan conflict is well documented with at 
least some chain of command approval.[28] Safety fears were highlighted after a friendly 
fire incident resulting in the death of four Canadian soldiers while the pilots had been 
taking dextroamphetamine.[29] Medical performance enhancement in the military 
environment thus shares with enhancement in sport concerns about risks and safety. 
Such concerns may be exacerbated by suspicions that it may have been utilised in secret, 
and without formal well-designed trials to assess safety and efficacy.[30] Other concerns 
around pharmacological enhancement include how prescription of medication for non-
therapeutic purposes could affect the doctor-patient relationship and how regulatory and 
professional bodies would view this, including the use of medicines outside their licenced 
indication. For these reasons, additional ethical considerations are raised by type 2 LOB-
ITs, and Mehlman et al. [6] provide a useful starting point (see Table 4) for exploring 
these. We are not proposing here the introduction of enhancement medicine for the 
purpose of enhancement. Rather, we are proposing that Type 2 LOB-ITs that fulfil all of 
the relevant ethical criteria (Tables 2-4) may be acceptable for use in combat despite 
their unintended but foreseen enhancing effects in circumstances of elevated risk. A 
LOB-IT intervention may be justified in one situation (high risk of trauma) without it 
automatically following that the same intervention would be justified in circumstances 
where intended effect was primarily that of enhancement.  
 
Might enhancing interventions lead to an escalation of force? 
The Geneva Convention (Chapter 4, Rule 14) stipulates that the principle of 
proportionality is adhered to when applying lethal force. If one side improves its defensive 
capability this may, in turn, justify larger and more destructive weapons being used by the 
other side as a proportionate measure. The use of LOB-IT could be perceived as an 
escalation of defensive capability by a belligerent party ultimately leading to a greater 
burden of suffering and harm than would otherwise have occurred. Whether physiological 
or anatomical enhancement of combatants might be used by an adversary to justify more 
destructive weaponry is not known, and has not been discussed in military doctrine or the 
military medical literature. It is unlikely that LOB-IT would be so effective as to justify 
escalation of force by a belligerent party. However, unfounded belief about the 
effectiveness of enhancement could potentially lead to use of greater force than would 
otherwise be justified if this belief was not operating. Such an escalation in the use of 
force may outweigh any benefits of the LOB-IT. This further highlights the importance of 
discussion to establish consensus as to the threshold of what constitutes an 
“enhancement” and what the justifiable military response to such an enhancement might 
be in terms of the Law of Armed Conflict. 
 
 
 
 
 
 
 
 
Table 4 – Ethics of Medical Enhancement In A Military Context (Modified from 
Mehlman et al. 2013[6]) 
 
Legitimate 
Military Purpose 
The enhancement must be used for legitimate military ends and the 
military purpose must be both legitimate and legal 
Necessity There must be no other way to achieve the desired outcome 
Benefits 
Outweigh Risks 
Benefits in this sense include those of the state, the unit, and the 
mission in addition to the individual involved. Risks include those to 
both combatants and civilians 
Maintenance of 
Individual’s 
Dignity 
Enhancements that undermine the combatants dignity (e.g. through 
the induction of compromising appearance or behaviour) should be 
avoided 
Minimisation of 
Burdens 
The burden of the enhancement should be time-limited or 
reversible so that the combatant may return to civilian life with no 
lasting effects of the enhancement 
Consent As long as enhancement is considered an experimental process or 
carries “exceptional” risk, it should be given to combatants only with 
their informed consent 
Transparency As far as it is consistent with security considerations, information on 
military medical enhancement research and utilisation should be 
made available to the public or at least an independent third party 
in order to counter the negative perception of such research 
conducted in secret in the past 
Fair Distribution 
of Risks and 
Benefits 
Enhancements should be offered to combatants in a fair, rational, 
and justifiable way such that utility is maximised. Enhancements 
should not be allowed to confer unfair benefits such as increased 
performance in promotion or selection processes 
Commanders are 
Accountable 
Combatants must be protected from coercion and unethical or 
illegal use of enhancements. Commanders retain ultimate 
responsibility for the use of enhancement and any subsequent 
consequences that follow 
 
 
 
 
 
 
 
 
 
CONCLUSION 
We have outlined some of the ethical implications of left-of-bang interventions in trauma. 
We have suggested that Type 1 (purely prophylactic) interventions may be implemented 
in a similar manner to any experimental prophylaxis: that is to say, according to the 
ethical principles of medical research and prophylaxis use and taking into account the 
military context. Once the efficacy and risks of a LOB-IT are established, its use may be 
on a par with any other prophylactic interventions used by the military. In the case of 
Type 2 (prophylaxis with enhancement) interventions, additional ethical safeguards may 
be required due to its unintended side-effects. Our aim is start wider discussion with a 
view to achieving some consensus in the longer term regarding the delivery of “left of 
bang” interventions in future conflicts. 
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